Inflarx (NASDAQ:IFRX) Stock Price Down 5.3%

Shares of Inflarx NV (NASDAQ:IFRX) dropped 5.3% during trading on Friday . The company traded as low as $2.68 and last traded at $2.69, approximately 503,166 shares changed hands during mid-day trading. A decline of 42% from the average daily volume of 861,307 shares. The stock had previously closed at $2.84.

IFRX has been the subject of a number of recent analyst reports. Robert W. Baird cut shares of Inflarx from an “outperform” rating to a “neutral” rating and lowered their target price for the stock from $58.00 to $6.00 in a research note on Wednesday, June 5th. ValuEngine upgraded shares of Inflarx from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Svb Leerink cut shares of Inflarx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 5th. Leerink Swann cut shares of Inflarx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, June 5th. Finally, SunTrust Banks cut shares of Inflarx from a “buy” rating to a “hold” rating and lowered their target price for the stock from $55.00 to $5.00 in a research note on Wednesday, June 5th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $15.66.

The firm’s 50 day simple moving average is $2.92 and its 200 day simple moving average is $25.81. The firm has a market capitalization of $69.84 million, a price-to-earnings ratio of -1.92 and a beta of -1.53.

Inflarx (NASDAQ:IFRX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.11). As a group, research analysts expect that Inflarx NV will post -2.25 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of IFRX. A.R.T. Advisors LLC lifted its stake in shares of Inflarx by 145.8% in the 2nd quarter. A.R.T. Advisors LLC now owns 29,162 shares of the company’s stock valued at $92,000 after purchasing an additional 17,300 shares during the period. Alpine Global Management LLC acquired a new position in shares of Inflarx in the 2nd quarter valued at $95,000. D. E. Shaw & Co. Inc. lifted its stake in shares of Inflarx by 23.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 84,863 shares of the company’s stock valued at $268,000 after purchasing an additional 15,962 shares during the period. Atria Investments LLC acquired a new position in shares of Inflarx in the 2nd quarter valued at $297,000. Finally, Citadel Advisors LLC lifted its stake in shares of Inflarx by 5.1% in the 2nd quarter. Citadel Advisors LLC now owns 99,935 shares of the company’s stock valued at $316,000 after purchasing an additional 4,840 shares during the period. Hedge funds and other institutional investors own 51.40% of the company’s stock.

Inflarx Company Profile (NASDAQ:IFRX)

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Further Reading: Stop Order

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.